DE69012138T2 - Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten. - Google Patents

Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.

Info

Publication number
DE69012138T2
DE69012138T2 DE69012138T DE69012138T DE69012138T2 DE 69012138 T2 DE69012138 T2 DE 69012138T2 DE 69012138 T DE69012138 T DE 69012138T DE 69012138 T DE69012138 T DE 69012138T DE 69012138 T2 DE69012138 T2 DE 69012138T2
Authority
DE
Germany
Prior art keywords
spin
trapping
administration
oxide
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69012138T
Other languages
English (en)
Other versions
DE69012138D1 (de
Inventor
John Carney
Robert Floyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/422,651 external-priority patent/US5025032A/en
Application filed by Oklahoma Medical Research Foundation, University of Kentucky Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of DE69012138D1 publication Critical patent/DE69012138D1/de
Publication of DE69012138T2 publication Critical patent/DE69012138T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69012138T 1989-10-17 1990-10-17 Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten. Expired - Fee Related DE69012138T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/422,651 US5025032A (en) 1989-10-17 1989-10-17 Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
US58917790A 1990-09-27 1990-09-27
PCT/US1990/005952 WO1991005552A1 (en) 1989-10-17 1990-10-17 Method and compositions for inhibition of disorders associated with oxidative damage

Publications (2)

Publication Number Publication Date
DE69012138D1 DE69012138D1 (de) 1994-10-06
DE69012138T2 true DE69012138T2 (de) 1995-04-06

Family

ID=27025701

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69012138T Expired - Fee Related DE69012138T2 (de) 1989-10-17 1990-10-17 Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.

Country Status (12)

Country Link
US (4) US5405874A (de)
EP (1) EP0496796B1 (de)
JP (5) JP2620413B2 (de)
KR (1) KR960008230B1 (de)
AT (1) ATE110565T1 (de)
AU (4) AU653921B2 (de)
CA (1) CA2069961C (de)
DE (1) DE69012138T2 (de)
DK (1) DK0496796T3 (de)
ES (1) ES2044829T3 (de)
HK (1) HK1007281A1 (de)
WO (1) WO1991005552A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE110565T1 (de) * 1989-10-17 1994-09-15 Oklahoma Med Res Found Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
US5681845A (en) * 1989-10-17 1997-10-28 Oklahoma Medical Research Foundation DMPO spin trapping compositions and methods of use thereof
ATE209908T1 (de) * 1991-06-18 2001-12-15 Oklahoma Med Res Found RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US5292746A (en) * 1991-09-12 1994-03-08 Merrell Dow Pharmaceuticals Inc. Cyclic nitrones, pharmaceutical compositions thereof and their use in treating shock
TW257755B (de) * 1991-09-12 1995-09-21 Merrell Dow Pharma
JPH0656669A (ja) * 1992-06-11 1994-03-01 Asahi Breweries Ltd 活性酸素消去作用を持つプテリン誘導体製剤
WO1995011908A1 (en) * 1993-10-25 1995-05-04 Oklahoma Medical Research Foundation Novel phosphorus-containing spin-trap compositions
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
FR2731428B1 (fr) * 1995-03-06 1997-06-06 Centre Nat Rech Scient Derives phosphoryles de nitrones, leur procede de preparation et compositions les contenant
ATE293604T1 (de) * 1995-09-11 2005-05-15 Aventis Pharma Inc Cyclische nitrone und pharmazeutische mittel die sie enthalten
ATE349420T1 (de) 1995-11-17 2007-01-15 Florida Internat University Azulenylnitrone als radikal fanger (spin trapping agents), verfahren zu ihrer herstellung und ihre anwendung
AU725432B2 (en) * 1996-04-17 2000-10-12 Centaur Pharmaceuticals, Inc. Nitrone free radical trap treatment of dementia associated with AIDS virus (HIV-1) infection
ATE263559T1 (de) * 1996-04-23 2004-04-15 Centaur Pharmaceuticals Inc Zubereitungen enhaltend eine nitroneverbindung für die verwendung bei der behandlung von uveitis
US5900227A (en) * 1996-06-17 1999-05-04 Oklahoma Medical Research Foundation Multicyclic nitrone spin trapping compositions
KR20000067915A (ko) * 1996-07-19 2000-11-25 센토르 파마슈티칼스, 인크. 푸란 니트론 화합물
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
MA26553A1 (fr) 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
WO1999036415A1 (en) * 1998-01-16 1999-07-22 Centaur Pharmaceuticals, Inc. Thioether furan nitrone compounds
JP2002509147A (ja) * 1998-01-16 2002-03-26 センター ファーマシューティカルズ， インコーポレイテッド チオフェンニトロン化合物
ATE267804T1 (de) 1998-07-17 2004-06-15 Renovis Inc Alpha-(2-hydroxyphenyl)nitrone, diese enthaltenden pharmazeutische zubereitungen sowie deren verwendung zur behandlung von entzündungen
UA66401C2 (en) * 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
WO2000074672A1 (en) * 1999-06-09 2000-12-14 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
AU785365B2 (en) * 2000-03-30 2007-02-08 Oklahoma Medical Research Foundation Butylnitrone containing compositons for inhibition of cancer development
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
WO2002065993A2 (en) 2001-01-08 2002-08-29 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) * 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US6762322B1 (en) * 2002-12-20 2004-07-13 Goodyear Tire & Rubber Company Preparation of nitrone derivatives
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
US7125934B1 (en) 2005-06-28 2006-10-24 The Goodyear Tire & Rubber Company Functionalization of living rubbery polymers with nitrones
WO2008013866A2 (en) * 2006-07-25 2008-01-31 Hough Ear Institute Methods for treating acute acoustic trauma
WO2009102808A2 (en) * 2008-02-12 2009-08-20 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
WO2009110585A1 (ja) * 2008-03-07 2009-09-11 国立大学法人熊本大学 電子スピン共鳴測定用試料溶液及びその乾固物，並びにそれらを用いた測定方法
KR20120007047A (ko) * 2009-04-20 2012-01-19 볼보 컨스트럭션 이큅먼트 에이비 통합 포장 시스템 및 방법
US9034926B2 (en) 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
US8986739B2 (en) 2011-02-28 2015-03-24 Nicholas V. Perricone Treatment of urinary incontinence using nitrone spin traps
ES2395803B1 (es) * 2011-08-01 2013-12-19 Consejo Superior De Investigaciones Científicas (Csic) - 80% Quinolilnitronas
DE102011088787A1 (de) 2011-12-16 2013-06-20 Evonik Industries Ag Siloxannitrone und deren Anwendung
WO2022169642A1 (en) * 2021-02-08 2022-08-11 Oklahoma Medical Research Foundation Okn-007 as a therapeutic agent for neurodegenerative diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35112A (en) * 1862-04-29 Improvement in head-rests for car-seats
US35213A (en) * 1862-05-13 Improved hydrant
DE273702C (de) *
US3396027A (en) * 1964-05-13 1968-08-06 Eastman Kodak Co Method of noodling gelatin dispersions
NL131665C (de) 1964-05-18
US3296145A (en) * 1965-10-21 1967-01-03 Millmaster Onyx Corp Quaternary ammonium-tertiary amine oxide compositions
US3775122A (en) * 1967-07-28 1973-11-27 American Can Co Image production using photosensitive compositions of nitrone which is heat developed
US3834073A (en) * 1971-05-03 1974-09-10 Scm Corp Phenyl nitrone derivatives useful as seed protectants
US3849934A (en) * 1971-05-03 1974-11-26 Scm Corp Alpha-aryl-n-lower alkyl nitrone-containing compositions useful as anti-fungal agents
US3767818A (en) * 1971-05-03 1973-10-23 Scm Corp Phenyl nitrone containing compositions useful as anti microbial agents
GB1531278A (en) * 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
GB1588417A (en) * 1977-03-15 1981-04-23 Agfa Gevaert Photoresist materials
US4224340A (en) * 1977-10-06 1980-09-23 William H. Rorer, Inc. Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds
US4197314A (en) * 1977-10-06 1980-04-08 William H. Rorer, Inc. Method of treating inflammation
US4214003A (en) * 1977-10-06 1980-07-22 William H. Rorer, Inc. Method of treatment
US4153722A (en) * 1977-10-06 1979-05-08 William H. Rorer, Inc. Method of treatment
US4870002A (en) * 1981-04-07 1989-09-26 The United States Of America As Represented By The Secretary Of The Air Force Method of prevention of oxidative injury to cells
WO1988005044A1 (en) * 1986-12-29 1988-07-14 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
WO1988005653A1 (en) * 1987-01-28 1988-08-11 Proctor Peter H Topical composition for stimulating hair growth with stable free radicals
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
ATE110565T1 (de) * 1989-10-17 1994-09-15 Oklahoma Med Res Found Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
JP2816326B2 (ja) 1998-10-27
JPH0925263A (ja) 1997-01-28
KR960008230B1 (ko) 1996-06-21
US5681965A (en) 1997-10-28
JP2002179563A (ja) 2002-06-26
KR920702220A (ko) 1992-09-03
ES2044829T1 (es) 1994-01-16
AU653921B2 (en) 1994-10-20
DE69012138D1 (de) 1994-10-06
AU6613390A (en) 1991-05-16
JPH05505792A (ja) 1993-08-26
DK0496796T3 (da) 1994-10-03
HK1007281A1 (en) 1999-04-09
CA2069961A1 (en) 1991-04-18
JP2620413B2 (ja) 1997-06-11
JPH10259178A (ja) 1998-09-29
AU8310298A (en) 1998-10-22
AU710341B2 (en) 1999-09-16
AU710342B2 (en) 1999-09-16
US6107315A (en) 2000-08-22
ATE110565T1 (de) 1994-09-15
AU692197B2 (en) 1998-06-04
JP2975587B2 (ja) 1999-11-10
AU1131595A (en) 1995-03-23
WO1991005552A1 (en) 1991-05-02
EP0496796A1 (de) 1992-08-05
JPH10259128A (ja) 1998-09-29
US5578617A (en) 1996-11-26
EP0496796B1 (de) 1994-08-31
AU8310198A (en) 1998-12-24
CA2069961C (en) 2000-05-02
ES2044829T3 (es) 1995-01-16
US5405874A (en) 1995-04-11

Similar Documents

Publication Publication Date Title
DE69012138T2 (de) Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten.
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
NO882732D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
ATE135375T1 (de) Glykosaminoglykan-modifiertes protein, verfahren zu dessen herstellung und pharmazeutische zubereitungen, die es enthalten
DE3783356T2 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
ATA95989A (de) Pyridoncarbonsäurederivate und salze hievon, verfahren zur herstellung derselben und antibakterielle mittel, welche diese enthalten
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
DE3878313T2 (de) Taurohyodeoxycholsaeure zur behandlung von gallenwegssteinen und gallenstoerungen.
DE68923151T2 (de) Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen.
DK393188D0 (da) Farmaceutisk praeparat til intranasal administrering
DK122391D0 (da) Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
IL85228A0 (en) 1-(4-hydroxy-3,5-di-tert-butylbenzoyl homopiperazine,various derivatives thereof,processes for the preparation of these compounds,medicaments containing them
DE58904722D1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
NO893256L (no) Fremgangsmaate for fremstilling av furyltiazolderivater.
DK1231908T3 (da) Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
ATE372785T1 (de) Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren
DE60024969D1 (de) 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten
NO920524D0 (no) Kynurensyrederivater, deres fremstilling og farmasoeytiskeblandinger inneholdende disse
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
BR9912423A (pt) Compostos e/ou derivados farmaceuticamente aceitáveis, composições farmacêuticas, métodos de tratamento das disordens neurológicas em pacientes e processos de preparação dos compostos ou derivados farmaceuticamente aceitáveis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee